Your Evaluation and Diagnostic Tests
At a Glance
Genitourinary Syndrome of Menopause (GSM) is diagnosed through a detailed symptom history, a physical exam assessing tissue health, and objective lab tests. A vaginal pH above 5.0 and a Vaginal Maturation Index showing a high number of immature parabasal cells confirm the diagnosis.
When you visit your doctor for urogenital symptoms, the goal of the appointment is to translate your lived experience into objective medical data. A diagnosis of Genitourinary Syndrome of Menopause (GSM) is reached through a combination of your medical history and specific findings from a physical examination and laboratory tests [1][2].
The Physical Examination: What the Doctor Sees
During a pelvic exam, your healthcare provider is looking for physical markers of estrogen deficiency [3]. Because urogenital tissues depend on estrogen to stay thick and elastic, its absence creates visible changes:
- Loss of Rugae: In an estrogen-rich environment, the vaginal walls have healthy folds called rugae. In GSM, these folds often flatten out, leaving the tissue looking smooth [4].
- Pallor: Healthy tissue is typically a robust pink. Atrophic tissue may appear pale (pallor) because of reduced blood flow to the area [5][4].
- Friability and Petechiae: The tissue can become so thin and fragile (friability) that it bleeds easily when touched. You might see small red spots called petechiae, which are tiny areas of bleeding under the surface [5][4].
- Elasticity and Moisture: The doctor will assess how well the tissues stretch and the amount of natural lubrication present [4].
Laboratory Indicators: Objective Data
Beyond what is visible to the eye, your doctor may use objective tests to confirm the diagnosis and measure the severity of the condition.
Vaginal pH
In your reproductive years, the vagina is a naturally acidic environment (typically with a pH below 4.5), which helps protect against infection [6]. When estrogen levels drop, the population of “good” bacteria (Lactobacillus) decreases, causing the pH to rise [6][7]. A vaginal pH greater than 5.0 is a classic objective indicator of GSM [8][9].
Vaginal Maturation Index (VMI)
This test involves taking a small swab of cells from the vaginal wall and looking at them under a microscope. Cells are categorized by their “maturity”:
- Superficial Cells: These are mature, “healthy” cells found when estrogen levels are sufficient [10].
- Parabasal Cells: These are immature, “younger” cells.
In GSM, there is a distinct shift: the number of superficial cells drops significantly, while the number of parabasal cells increases [8][11]. Seeing a high percentage of parabasal cells confirms that the tissue is not receiving enough estrogenic stimulation [11][12].
Your Evaluation Completeness Checklist
To ensure your diagnosis is accurate and that no “mimic” conditions are missed, a thorough evaluation should ideally include:
- A detailed symptom history (including urinary and sexual health) [5].
- A visual inspection of the vulva and vagina for signs of thinning or architectural changes [4].
- A pH test to measure the acidity of the vaginal environment [8].
- A urine culture if you have urinary symptoms, to rule out a true infection [5].
- A review of previous treatments and how you responded to them [13].
If your symptoms persist after starting treatment, your doctor should revisit the diagnosis to ensure other conditions like Lichen Sclerosus or Vulvodynia are not the primary cause [2][13].
Common questions in this guide
How is Genitourinary Syndrome of Menopause (GSM) diagnosed?
What does a high vaginal pH mean during menopause?
What is a Vaginal Maturation Index (VMI) test?
What physical signs of vaginal atrophy does a doctor look for?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.During my exam, did you notice a loss of rugae (vaginal folds) or any specific signs of tissue thinning like pallor or petechiae?
- 2.What was my vaginal pH during the exam, and what does that number tell you about my estrogen levels?
- 3.Are you ordering a Vaginal Maturation Index (VMI)? If so, can you explain what my ratio of parabasal cells to superficial cells means for my diagnosis?
- 4.Based on my symptoms and the exam, how would you score me on the Vaginal Health Index (VHI)?
- 5.If my symptoms don't improve with the treatment we're starting, what is our next step for ruling out other look-alike conditions?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
The Genitourinary Syndrome of Menopause: An Overview of the Recent Data.
Angelou K, Grigoriadis T, Diakosavvas M, et al.
Cureus 2020; (12(4)):e7586 doi:10.7759/cureus.7586.
PMID: 32399320 - 2
Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy.
Pérez-López FR, Vieira-Baptista P, Phillips N, et al.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2021; (37(8)):740-745 doi:10.1080/09513590.2021.1931100.
PMID: 34036849 - 3
Modern approach to the management of genitourinary syndrome in women with gynecological malignancies.
Kovacevic N, Cilensek I, Merlo S, Segedin B
Radiology and oncology 2023; (57(3)):292-298 doi:10.2478/raon-2023-0038.
PMID: 37494601 - 4
Effect of zinc-containing pessaries on menopausal genitourinary syndrome, a double-blind randomised trial.
Mousa A, Elgarhi I, Ibrahim B, et al.
BMC women's health 2025; (25(1)):467 doi:10.1186/s12905-025-04037-y.
PMID: 41044538 - 5
Genitourinary syndrome of menopause: in their own words-development of a new patient-reported outcome measure.
Kling JM, Faubion SS
Menopause (New York, N.Y.) 2019; (26(4)):335-336 doi:10.1097/GME.0000000000001309.
PMID: 30724847 - 6
Expert Opinion on the Use of Probiotics in General Gynecological Conditions.
Patki A, Pandit S, Ashraf N, et al.
Cureus 2025; (17(3)):e80875 doi:10.7759/cureus.80875.
PMID: 40255841 - 7
Change in microbiota profile after vaginal estriol cream in postmenopausal women with stress incontinence.
Moore KH, Ognenovska S, Chua XY, et al.
Frontiers in microbiology 2024; (15()):1302819 doi:10.3389/fmicb.2024.1302819.
PMID: 38505551 - 8
Effective Prevention of Recurrent UTIs With Vaginal Estrogen: Pearls for a Urological Approach to Genitourinary Syndrome of Menopause.
Buck ES, Lukas VA, Rubin RS
Urology 2021; (151()):31-36 doi:10.1016/j.urology.2020.05.058.
PMID: 32533967 - 9
The Impact of Local Estrogen on the Urogenital Microbiome in Genitourinary Syndrome of Menopause: A Randomized-Controlled Trial.
Lillemon JN, Karstens L, Nardos R, et al.
Female pelvic medicine & reconstructive surgery 2022; (28(6)):e157-e162 doi:10.1097/SPV.0000000000001170.
PMID: 35420551 - 10
Urogenital Atrophy in 40-75 Years Women Assessed with Different Scoring Systems at Tertiary Care Hospital of India.
Shah M, Khandelwal A, Patel S
Journal of mid-life health 2018; (9(4)):191-194 doi:10.4103/jmh.JMH_15_18.
PMID: 30692814 - 11
A phase 1/2, open-label, parallel group study to evaluate the preliminary efficacy and usability DARE-HRT1 (80 μg estradiol/4 mg progesterone and 160 μg estradiol/8 mg progesterone intravaginal RinGSM) over 12 weeks in healthy postmenopausal women.
Thurman A, Hull ML, Stuckey B, et al.
Menopause (New York, N.Y.) 2023; (30(9)):940-946 doi:10.1097/GME.0000000000002230.
PMID: 37625088 - 12
The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial.
Zohrabi I, Abedi P, Ansari S, et al.
BMC women's health 2020; (20(1)):108 doi:10.1186/s12905-020-00935-5.
PMID: 32429977 - 13
Assessment and Treatment of Vaginitis.
Mitchell CM
Obstetrics and gynecology 2024; (144(6)):765-781 doi:10.1097/AOG.0000000000005673.
PMID: 38991218
This information about Genitourinary Syndrome of Menopause (GSM) diagnostic tests is for educational purposes only. Always consult your gynecologist or healthcare provider for a clinical evaluation and accurate diagnosis.
Get notified when new evidence is published on postmenopausal atrophic vaginitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.